Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals RNS Release

Holding(s) in Company

RNS Number : 9985P
GW Pharmaceuticals PLC
24 November 2016
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

GW Pharmaceuticals PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

x

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to the
notification obligation:
iii

The Goldman Sachs Group, Inc.

4. Full name of shareholder(s)
 (if different from 3.):iv

Goldman Sachs International

Goldman, Sachs & Co.

Goldman Sachs Asset Management, L.P.

5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

18 November 2016

6. Date on which issuer notified:

22 November 2016

7. Threshold(s) that is/are crossed or
reached:
vi, vii

Below 3%

         
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB0030544687

94,532

94,532

 

 

Below 3%

 

Below 3%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 

 

 

Below 3%

Below 3%

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

 

 

 

 

Below 3%

 

Below 3%

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Below 3%

Below 3%

                         

 

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 

N/A

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A

 


13. Additional information:

General email contact:

[email protected]

 

14. Contact name:

Joanna Foley

15. Contact telephone number:


+44 207 051 9996

 

     

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAPFDAEAKFFF



GW Pharmaceuticals Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use